Progyny Inc
$ 25.65
-0.93%
11 Jun - close price
- Market Cap 2,028,025,000 USD
- Current Price $ 25.65
- High / Low $ 26.09 / 25.50
- Stock P/E 33.62
- Book Value 6.24
- EPS 0.77
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.15 %
- 52 Week High 28.75
- 52 Week Low 16.10
About
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$29.73
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 |
| Reported EPS | 0.29 | 0.48 | 0.15 | 0.48 | 0.48 | 0.42 | 0.4 | 0.43 | 0.39 | 0.13 | 0.16 | 0.15 |
| Estimated EPS | 0.26 | 0.14 | 0.13 | 0.43 | 0.45 | 0.37 | 0.37 | 0.4 | 0.35 | 0.11 | 0.11 | 0.1 |
| Surprise | 0.03 | 0.34 | 0.02 | 0.05 | 0.03 | 0.05 | 0.03 | 0.03 | 0.04 | 0.02 | 0.05 | 0.05 |
| Surprise Percentage | 11.5385% | 242.8571% | 15.3846% | 11.6279% | 6.6667% | 13.5135% | 8.1081% | 7.5% | 11.4286% | 18.1818% | 45.4545% | 50% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PGNY
2026-06-10 14:10:07
Progyny (PGNY) recently secured shareholder approval to remove a supermajority voting requirement for certain business combinations and initiated a new US$200 million share repurchase program, building on previous buybacks. These actions, alongside positive analyst commentary, signal management's confidence and an evolving approach to shareholder alignment. While the buyback program doesn't alter fundamental demand and competition risks in the fertility and women's health benefits market, it aims to soften share price volatility and concentrate ownership among remaining shareholders.
2026-06-10 07:10:07
Progyny, Inc. (PGNY) has approved a change to its Certificate of Incorporation, removing a supermajority voting requirement for certain business combinations, and authorized a US$200 million share repurchase program. These actions are intended to enhance shareholder voting flexibility and demonstrate management's confidence in the company's financial position and future prospects. The article discusses how these changes, alongside the launch of Progyny Select for small employers, might influence the company's investment narrative and risk profile, especially concerning employer demand for fertility benefits.
2026-06-08 18:04:08
Progyny Inc. (PGNY) stock has experienced recent share price fluctuations, drawing investor attention to its role as a fertility benefits specialist. The company provides employer-sponsored fertility and family-building benefits in the US, focusing on managed care, curated clinic networks, and integrated pharmacy solutions. Its growth is driven by employer adoption and perceived value, though it remains sensitive to broader healthcare spending and labor market conditions.
2026-06-08 16:39:08
Progyny, Inc. filed a Schedule 13G/A Amendment No. 4, indicating that Kleiner Perkins entities report zero beneficial ownership and 0% of the class. This amendment, signed by Susan Biglieri on June 5, 2026, is a routine ownership disclosure rather than a transaction notice, confirming that Kleiner Perkins holds no voting or dispositive power over PGNY shares.
2026-06-06 19:41:03
Progyny (NASDAQ:PGNY) Executive Vice President Allison Swartz sold 599 shares of company stock valued at approximately $15,022.92 on June 4th, with a previous sale of 1,199 shares on June 3rd. Following these transactions, Swartz still holds 82,378 shares. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, and the company recently reported strong quarterly earnings, and initiated a $200 million share repurchase program.
2026-06-06 06:40:03
Progyny's CFO, Mark Livingston, sold $64,183 worth of company stock through a Rule 10b5-1 trading plan. These sales occurred around the time 1,421 shares were withheld for tax payments related to restricted stock units. Despite the insider sale, Progyny reported strong first-quarter financial results and received upgraded ratings and price targets from analysts, indicating a positive outlook for the company.
